Standard Biotools Inc. has achieved a regulatory milestone with the notice of effectiveness for its latest filing. This development is crucial for the company as it may pave the way for future growth and opportunities.
Standard Biotools Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates on the Nasdaq under the ticker LAB. The company has been active in the market, with recent filings indicating ongoing strategic initiatives to enhance its position in the industry.
The recent filing, dated October 21, 2026, includes a notice of effectiveness, which signifies that the SEC has accepted the filing. The filing states, "Accepted 2026-10-22 00:15:03" and confirms the effectiveness date as October 21, 2026.
This update could impact various stakeholders, including investors, partners, and competitors within the pharmaceutical preparations sector. As Standard Biotools Inc. progresses, it may influence market dynamics and competitive strategies.
The filing does not say what happens next.
Company Overview
Standard Biotools Inc. is incorporated in Delaware and operates under the Central Index Key (CIK) number 0001162194. The company has a fiscal year ending on December 31st and is classified under the SIC code 2834 for Pharmaceutical Preparations.
The filing also includes the company's Employer Identification Number (EIN), which is 770513190. This information is relevant for stakeholders seeking to understand the corporate structure and compliance of Standard Biotools Inc.
Contact Information
The business address for Standard Biotools Inc. is located at 50 Milk Street, 10th Floor, Boston, MA 02109. This address serves as both the mailing and business address, providing a point of contact for investors and partners.
"Accepted 2026-10-22 00:15:03" indicates the official acceptance time of the filing by the SEC.
While the filing confirms the effectiveness date and provides essential company information, it does not elaborate on any specific plans or future actions that Standard Biotools Inc. may undertake following this regulatory milestone.